Alzheimers Disease and other Cognitive Disorders
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Right Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Most Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyAHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?Dementia Risk Rises as Years Lived With Type 2 Diabetes IncreasesHead Injury, Alzheimer's Appear to Affect Brain in Similar WaysResearch Shows Links Between Gum Disease and Alzheimer's
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Drug Shows Promise in Easing Dementia-Linked Psychosis

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Jul 23rd 2021

new article illustration

FRIDAY, July 23, 2021 (HealthDay News) -- A drug that eases hallucinations in people with Parkinson's disease may be able to do the same for those with dementia, a new clinical trial finds.

The medication, called Nuplazid (pimavanserin), is already approved in the United States for treating hallucinations and delusions related to Parkinson's.

The new study, published July 22 in the New England Journal of Medicine, suggests the drug may help dementia patients plagued by those same symptoms.

Researchers found that over 18 weeks, patients given Nuplazid were 65% less likely to see a resurgence of their hallucinations and delusions, compared to those on a placebo.

The trial had been planned to run longer, but was stopped early when it became clear the drug was effective.

Experts said the findings offer hope of a new treatment for some of the more troubling symptoms of dementia. But longer-term studies are still needed.

"I don't want people to think this is a miracle drug. It isn't," said lead researcher Dr. Pierre Tariot, director of Banner Alzheimer's Institute in Phoenix.

But, he added, the findings suggest Nuplazid could help many patients with dementia-related psychosis — possibly without all the risks of current medications.

Alzheimer's disease and other forms of dementia are commonly seen as memory disorders, but they affect the whole brain. And it's the psychiatric and behavioral symptoms — including delusions, hallucinations, agitation and aggression — that can be the most difficult for patients and caregivers.

It's common, for example, for patients to believe that people are constantly trying to steal their possessions, said Dr. Joseph Friedman, an associate professor of psychiatry and neuroscience at Icahn School of Medicine at Mount Sinai in New York City.

It's a false belief, but one that can be very distressing, Friedman said.

Hallucinations, meanwhile, may involve seeing or hearing people who are not there. Friedman said that in some cases — if a person is seeing a long-dead loved one, for example — the hallucination may not be a negative experience.

In other cases, the imagined encounters can be frightening or trigger dangerous behaviors.

Right now, no medications are officially approved for managing dementia-related hallucinations and delusions. But doctors commonly prescribe antipsychotic medications — the types used for schizophrenia and bipolar disorder.

A big problem, Friedman said, is the drugs' side effects: Movement problems, sedation, dizziness and falls are among them.

"And chronic exposure to antipsychotics can actually worsen the cognitive decline," Friedman said.

In that context, he said, the new findings may offer families "hope that there's a possible alternative treatment out there."

Friedman wrote an editorial published with the study, which was funded by Nuplazid's maker, Acadia Pharmaceuticals.

The trial was conducted in separate stages. First, Tariot's team screened nearly 800 dementia patients who were having hallucinations and delusions. All patients and their caregivers were given counseling on how to deal with those symptoms without medication, which is what medical guidelines recommend.

Caregivers might, for example, offer reassurance or use distractions — like music or going for walk — when hallucinations or delusions arise.

After five weeks, 351 study patients were still having symptoms and entered an "open-label" trial: All were given Nuplazid for 12 weeks. Of those patients, 62% had a lasting response to the medication and moved on to the final trial phase.

At that point, about half were randomly assigned to stay with Nuplazid for another 26 weeks, while the others were switched to a placebo.

After 18 weeks, a clear difference emerged: 28% of placebo patients were suffering hallucinations or delusions again, compared with 13% of Nuplazid patients.

As for side effects, the most common were headache, constipation and urinary tract infection. Three patients showed a heart rhythm irregularity called a long QT interval — a known side effect of the drug. The labeling advises people with certain conditions that affect heart rhythm not to take the medication.

Friedman said longer-term data is still needed, and it's unclear whether Nuplazid works better for certain forms of dementia than others. The majority of study patients had Alzheimer's, but about one-third had dementia due to Parkinson's, vascular disease or a buildup of abnormal structures called Lewy bodies in the brain.

Tariot agreed that larger, longer trials are needed.

Given the current options for managing these symptoms, he said, "if we had something else we could use, that would be terrific."

There have, however, been no head-to-head comparisons of Nuplazid and standard antipsychotics, to gauge how much safer or more effective it might be, Tariot noted.

Nuplazid is much more expensive. When it came to market in 2016, it was reportedly at a cost of $24,000 a year.

More information

The Alzheimer's Association has more on hallucinations and delusions.

SOURCES: Pierre Tariot, MD, director, Banner Alzheimer's Institute, Phoenix; Joseph Friedman, MD, associate professor, psychiatry and neuroscience, Icahn School of Medicine at Mount Sinai, New York City; New England Journal of Medicine, July 22, 2021

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net